Open Letter: Biopharma Leaders Call For Diversity Drive
Executive Summary
An open letter signed by key figures in UK biopharma, calls on industry leaders, HR and recruitment organizations to increase diversity in sector boardrooms and C-suites, by facilitating the path of women and minorities to the top. They note that biopharma lags behind other industries and that all-male boards are associated with under-performance compared with mixed-gender boards of recently floated firms.
You may also be interested in...
Will New CEOs Make C-Suite More 'She-Suite'?
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.